Loading clinical trials...

Speech-to-text Tool for Heart Failure Patient-Reported Data | Clinical Trials | Clareo Health

ENROLLING_BY_INVITATIONNA

Speech-to-text Tool for Heart Failure Patient-Reported Data

Testing a Speech-to-text Tool for Heart Failure Patient-Reported Data

NCT07217366•Stanford University

Summary

The goal of this study is to see whether this type of Artificial Intelligence (AI) Voice Assistant can reliably capture patient-reported health information to support communication between patients and their healthcare team.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Adults with heart failure receiving cardiology care at Stanford University

Exclusion Criteria

•Diminished decision-making capacity
•Inability to understand and communicate in English sufficiently to complete study procedures
•Inability to complete study procedures to the best of the participant's and investigator's knowledge
•Any disorder or condition that, in the opinion of the investigator would pose a risk to participant safety or interfere with the study evaluation, procedures or completion

Locations (1)

Stanford University

Palo Alto, California, United States

Key Dates

Start Date

October 13, 2025

Primary Completion Date

May 1, 2026

Completion Date

June 1, 2026

Last Updated

March 9, 2026

Enrollment

100

ESTIMATED participants

Conditions

Heart Failure

Interventions

Artificial intelligence speech-to-text tool

OTHER

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

RECRUITING

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 9, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Speech-to-text Tool for Heart Failure Patient-Reported Data

Inclusion Criteria

Exclusion Criteria

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation